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Abstract
Background:  Nitric oxide (NO) and oxygen free-radicals play an important part in the
destruction of beta-cells in auto- immune diabetes although the precise mechanism of interaction
is still not known. This study was designed to examine any possible diabetogenic effect of NO by
investigating any differences in cellular binding of insulin to its receptor on the cell membranes of
eryt hrocy te s and  mononuc lear leucocyt e s of dogs tre at ed  wi th the NO donor, S-nit ros o-N-
acetylpenicillamine (SNAP) and controls treated with captopril.
Results: The result obtained showed decreased binding of insulin to its receptor on the cell
membranes of erythrocytes and mononuclear leucocytes. Mononuclear leucocytes from SNAP-
treated dogs had decreased ability to bind insulin (16.30 ± 1.24 %) when compared to mononuclear
leucocytes from captopril-treated controls (20.30 ± 1.93 %). Similar results were obtained for
erythrocytes from dogs treated with SNAP (27.20 ± 1.33 %) compared with dogs treated with
captopril (34.70 ± 3.58 %). Scatchard analysis demonstrated that this decrease in insulin binding was
accounted for by a decrease in insulin receptor sites per cell, with mononuclear leucocytes of
SNAP-treated dogs having 55 % less insulin receptor sites per cell compared with those of
captopril-treated controls (P < 0.05). Average affinity and kinetic analysis revealed a 35 % decrease
in the average receptor affinity, with mononuclear leucocytes from captopril-treated controls
having an empty site affinity of 12.36 ± 1.12 ×  10-8 M-1 compared with 9.64 ± 0.11 ×  10-8 M-1 in
SNAP-treated dogs (P < 0.05).
Conclusion: These results suggest that acute alteration of the insulin receptor on the membranes
of mononuclear leucocytes and erythrocytes occurred in dogs treated with S-nitroso-N-
acetylpenicillamine. These findings suggest the first evidence of the novel role of NO as a modulator
of insulin binding and the involvement of NO in the aetiology of diabetes mellitus.
Background
Nitric oxide (NO) is a physiologically important signal
molecule regulating a variety of biological functions such
as smooth muscle relaxation, neurotransmission, and im-
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mune processes. Excess induction of NO, however, has
also been implicated as a cause of diverse pathological
conditions such as inflammation, neuro-degenerative dis-
eases, cardiovascular disorders, and possibly cancer. These
detrimental effects of NO have been attributed to reactive
nitrogen species such as oxides of nitrogen (NOx) and per-
oxynitrite (ONOO-), which are formed by the reaction of
NO with oxygen and superoxide respectively [1]. Reactive
nitrogen species can oxidize, nitrate, and nitrosate bio-
molecules such as proteins, DNA, and lipids, thus altering
their functions.
S-nitroso-N-acetylpenicillamine has been shown to be po-
tent smooth muscle relaxants in a variety of vascular
smooth muscle preparations [2]. It has been shown to
produce significant inhibition of spontaneous contrac-
tions in myometrial strips from oestrogen-primed, and
progesterone-treated rats. The relaxant effect of SNAP was
found to be exerted by a mechanism independent of
cGMP elevation but may be due to the activation of a cal-
cium-activated potassium channel [3].
Experiments were also done with SNAP, to validate the
significance of NO in the development of diabetes. The re-
sults showed cleavage of the DNA into nucleosomal frag-
ments [4]. This NO donor cause the activation of
poly(ADP ribose) synthase in cell nuclei, and this activa-
tion depletes intracellular NAD+ by consuming it as its
substrate [5]. It is proposed that internucleosomal DNA
cleavage induced by NO activates poly(ADP ribose) syn-
thase, which in turn depletes intracellular NAD+ and caus-
es poly-ADP-ribosylation of nuclear proteins, resulting in
the deterioration of β -cell function [6].
Insulin binding to receptors is the first event in insulin ac-
tion, and this first step represents a major control point
for insulin's effects in vivo. Insulin binding to receptors is
not a fixed biologic process, but is subjected to modula-
tion by alterations in either receptor number or affinity
[7]. In the present study, we investigated the acute effects
of a dose of SNAP on the binding of insulin to its receptor
on the cell membranes of mononuclear leucocytes and
erythrocytes and whether an insulin-receptor defect is of
importance in the hyperglycemic condition.
Results
Figure 1 and Figure 2 summarizes the ability of non-radi-
oactive insulin to competitively inhibit the binding of 125-
I-insulin to the insulin receptor on the cell membranes of
mononuclear leucocytes and erythrocytes respectively, in
dogs treated with 20 mg/kg of SNAP, and controls treated
with 20 mg/kg of captopril or 2 ml of DMSO. Comparison
of the plots showed that insulin receptor on the cell mem-
branes of erythrocytes and mononuclear leucocytes from
dogs treated with SNAP binds significantly less 125-I-insu-
lin than cells from the captopril-treated controls and
those administered with 2 ml of DMSO at unlabelled in-
sulin concentrations.
The percentage 125-I-insulin bound to the insulin receptor
on the cell membrane of mononuclear leucocytes of dogs
treated with SNAP (16.3 0 ± 1.24 & 10.50 ± 1.14 %) was
significantly lower than the percentage 125-I-insulin
bound at 1.5 h to those of captopril-treated controls
(20.30 ± 1.93 & 16.00 ± 1.12 %) or controls administered
with DMSO (19.21 ± 2.21 & 14.15 ± 2.63 %) at very low
unlabelled insulin concentrations (0 and 1 ng/ml). Statis-
tical analysis of the percentage insulin bound at these low
insulin concentrations revealed that the differences for the
SNAP-treated and captopril-treated dogs were statistically
significant [P = 0.020 and P = 0.031; Figure 1. The remain-
der of the curve showed that percentage 125-I-insulin
bound in SNAP-treated dogs being appreciably less than
Figure 1
Competitive binding curves showing the effect of 20 mg/kg of
SNAP (), 20 mg/kg of captopril () and 2 ml of DMSO ()
on the binding of insulin to its receptor on mononuclear leu-
cocytes. Percentage of 125-I-insulin. bound is plotted as a
function of the unlabelled insulin concentration. Statistical
significant differences are indicated by *P < 0.05 and *P <
0.01.
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those of the captopril-treated controls, but not statistically
significant (P > 0.05), with the exception of the percentage
125-I-insulin bound at 2.5 ng/ml (P = 0.006).
A similar trend was seen on examination of the erythro-
cytes binding profile [Figure 2]. The maximum percentage
of 125-I-insulin bound to the insulin receptor using capto-
pril was 34.70 ± 3.58 % and dogs administered with DM-
SO, 32.60 ± 4.67 % compared with 27.20 ± 1.33 % for
erythrocytes of dogs  with SNAP (P > 0.05). Further anal-
ysis showed that the percentage of 125-I-insulin bound to
the insulin receptor on the cell membranes of erythrocytes
of SNAP-treated dogs at unlabelled insulin concentrations
greater than 0.5 ng/ml, were appreciably less and statisti-
cally significant than those of the captopril-treated con-
trols (P < 0.05). Comparison of the competition curves of
percentage 125-I-insulin bound to the insulin receptor on
erythrocytes of the SNAP-treated dogs and captopril-treat-
ed controls showed slopes that decreased steadily to val-
ues of 15.45 ± 1.02 % and 25.45 ± 1.76 % respectively (P
= 0.007) at an unlabelled insulin concentration of 10 ng/
ml. The integrated area under the curve for mononuclear
leucocytes from dogs treated with 20 mg/kg of SNAP was
88.65 ± 5.28 % ×  10 ng/ml compared with 131.76 ± 5.57
% ×  10 ng/ml in captopril-treated controls (P < 0.05) and
126.65 ± 4.3.28 % in dogs administered with DMSO.
In this study, bound/free (B/F) ratio of the labelled hor-
mone is expressed as a function of the bound hormone
giving a Scatchard Plot for mononuclear leucocytes [Fig-
ure 3] and erythrocytes [Figure 4]. Curvilinear plots were
obtained for the controls treated with 20 mg/kg of capto-
pril and 2 ml of DMSO, and dogs treated with 20 mg/kg
of SNAP. A greater B/F implies that there is more bound
hormone than free. Comparison of the plots showed that
insulin receptor on the cell membranes of mononuclear
leucocytes for captopril-treated controls and dogs treated
with DMSO had maximum B/F values of 0.221 ± 0.03 and
0.219 ± 0.13 respectively, compared with 0.182 ± 0.01 for
SNAP-treated dogs at the 1.5 h time interval (P < 0.05).
Further statistical analysis revealed that although the B/F
125-I-insulin ratios for the SNAP-treated dogs were appre-
ciably less than the captopril-treated controls, the differ-
ences were only statistically significant at an unlabelled
insulin concentration of 10 ng/ml (P = 0.017).
The slopes of both plots of the bound/free 125-I-insulin ra-
tio of the insulin receptor for erythrocytes from SNAP-
treated and captopril-treated dogs, are quite different, as
demonstrated in Figure 4. The bound/free 125-I-insulin ra-
tio of the insulin receptor of dogs treated with SNAP at the
1.5 h time point was 0.374 ± 0.03 compared with 0.531 ±
0.06 for dogs treated with captopril (P = 0.009) and 0.543
± 0.06 in DMSO-treated dogs. Further statistical analysis
of the Scatchard plots indicated that there were statistical-
ly significant differences in the bound/free 125-I-insulin
ratio of the insulin receptor for dogs treated with SNAP,
compared with the captopril-treated controls. This was ev-
ident at unlabelled insulin concentrations of 0.1 and 5 ng/
ml (P = 0.008 and P = 0.013 respectively).
To analyze these changes in affinity more precisely, the
data have been plotted on an average receptor affinity
graph as described by DeMeyts and Roth [8]. Graphical
representation for the average receptor affinity profiles is
depicted in Figures 5 and 6 at the 1.5-h time point. Exam-
ination of the slopes of the plots for mononuclear leuco-
cytes from SNAP-treated dogs and captopril-treated
controls are not different, especially at unlabelled insulin
concentrations of 5 ng/ml and 10 ng/ml. However, the av-
erage receptor affinity values of the SNAP-treated dogs
were slightly less than those of their captopril-treated
counterparts at the other unlabelled insulin concentra-
tions (P > 0.05).
Figure 2
Competitive binding curves showing the effect of 20 mg/kg of
SNAP (), 20 mg/kg of captopril () and 2 ml of DMSO ()
on the binding of insulin to its receptor on erythrocytes. Per-
centage of 125-I-insulin. bound is plotted as a function of the
unlabelled insulin concentration. Statistical significant differ-
ences are indicated by *P < 0.05 and *P < 0.01.
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Analysis of the data shows that mononuclear leucocytes of
dogs treated with captopril have an 'empty site' affinity
(Ke) of 12.36 ± 1.12 ×  10-8 M-1, which begin to decrease
when approximately 1.48 % of total receptor sites was oc-
cupied. With increasing occupancy of the receptor sites by
125-I-insulin, the average receptor affinity progressively
decreased to the 'filled site' affinity (Kf) of 5.23 ± 0.46 ×
10-8 M-1, when 71.02 % of available receptor sites were
occupied [Figure 5]. The comparable values of Ke and Kf
for mononuclear leucocytes of dogs administered with
DMSO were 11.25 ± 0.8 ×  10-8 M-1 (2.00 % receptor oc-
cupancy) and 5.03 ± 0.45 ×  10-8 M-1 (70.01 % receptor oc-
cupancy) respectively. The comparable values of Ke and Kf
for mononuclear leucocytes of dogs treated with 20 mg/kg
of SNAP were 9.64 ± 0.11 ×  10-8 M-1 (2.16 % receptor oc-
cupancy) and 4.80 ± 0.85 ×  10-8 M-1 (66.41 % receptor oc-
cupancy) respectively (P < 0.05). Further statistical
analysis of the data showed no significant differences in
the average receptor affinity values between the groups at
low unlabelled insulin concentrations (0.1 – 2.5 ng/ml).
A similar pattern was seen for the average receptor affinity
of the insulin receptor on the cell membrane of erythro-
cytes of the SNAP-treated dogs. The Ke value of the insulin
receptor for erythrocytes from dogs treated with SNAP was
8.56 ± 0.79 ×  10-8 M-1 when 2.61 % of available receptor
sites were occupied. This was lower than that of the capto-
pril-treated controls, 8.96 ± 0.91 ×  10-8 M-1 when 1.60 %
of available receptor sites were occupied (P > 0.05). The Ke
value of the insulin receptor for erythrocytes from dogs
administered with DMSO was 8.70 ± 0.68 ×  10-8 M -1
when 3.11 % of available receptor sites were occupied.
The calculated mean value for Kf for the captopril-treated
controls was 4.92 ± 0.43 ×  10-8 M-1 at an occupancy of
70.72 % compared with 4.53 ± 0.57 ×  10-8 M-1 at an oc-
cupancy of 78.30 % [Figure 6] for dogs treated with SNAP.
The calculated mean value for Kf for dogs treated with
Figure 3
Scatchard plot showing the effect of 20 mg/kg of SNAP (),
20 mg/kg of captopril () and 2 ml of DMSO () on the
binding of insulin to its receptor on mononuclear leucocytes.
Bound/Free ratio is plotted as a function of the insulin bound
(B). Statistical significant differences are indicated by *P <
0.05 and **P < 0.01.
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Figure 4
Scatchard plot showing the effect of 20 mg/kg of SNAP (),
20 mg/kg of captopril () and 2 ml of DMSO () on the
binding of insulin to its receptor on erythrocytes. Bound/
Free ratio is plotted as a function of the insulin bound (B).
Statistical significant differences are indicated by *P < 0.05
and **P < 0.01.
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DMSO was 4.84 ± 0.20 ×  10-8 M-1 at an occupancy level
of 71.5 %. The mean differences between empty and filled
site affinities of the insulin receptor on the erythrocyte cell
membrane of captopril-treated controls and SNAP-treated
dogs or between the values of DMSO-treated and SNAP-
treated dogs were not statistically significant (P > 0.05).
On administration of SNAP, a decrease in the number of
insulin receptor sites on the cell membrane on mononu-
clear leucocytes was observed in the dogs. There was a 55
% decrease in the number of insulin receptor sites per cell
of dogs treated with SNAP (11.90 ± 1.57 ×  104) compared
with that of mononuclear leucocytes for captopril-treated
controls (22.10 ± 1.81 ×  104) at the 1.5-h time point. The
number of insulin receptor sites per cell in dogs treated
administered with DMSO is 21.20 ± 1.25 ×  104. The dec-
rement in the insulin receptor sites per cell between
SNAP-treated and captopril-treated dogs was statistically
significant [P = 0.003, Figure 7].
Figure 8 showed that the number of insulin receptor sites
on the cell membrane of erythrocytes for SNAP-treated
dogs was appreciably less than those of captopril-treated
dogs at the 1.5-h time point. The calculated insulin recep-
tor sites per cell for dogs treated with captopril and DMSO
was 92 ± 6 and 89 ± 6 respectively, compared with 60 ± 4
insulin receptor sites per cell in dogs treated with SNAP at
the 1.5-h time point (P = 0.285).
Discussion
This study is a sequel to a previous study by McGrowder
et al. [9] which found that SNAP-treated dogs displayed
postprandial hyperglycaemia. Captopril was used as the
control drug based on results from a study conducted by
Winocour et al. [10] which found that low-dose therapy
had no significant effect on blood glucose control in hy-
pertensive insulin-treated diabetic individuals and that it
lowers blood pressure by a mechanism which is different
from SNAP. The study by McGrowder et al. [9] also report-
ed that SNAP at 20 mg/kg caused significant reduction of
Figure 5
Average affinity profile showing the effect of 20 mg/kg of
SNAP (), 20 mg/kg of captopril () and 2 ml of DMSO ()
on the binding of insulin to its receptor on mononuclear leu-
cocytes. Average receptor affinity is plotted as a function of
the receptor occupancy.
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Figure 6
Average affinity profile showing the effect of 20 mg/kg of
SNAP (), 20 mg/kg of captopril () and 2 ml of DMSO ()
on the binding of insulin to its receptor on erythrocytes.
Average receptor affinity is plotted as a function of the
receptor occupancy.
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the haemodynamic parameter, mean arterial pressure and
a significant increase in heart rate via the release of nitric
oxide. Captopril at a dose of 20 mg/kg had less of an effect
on both mean arterial and heart rate. The mean arterial
blood pressure-lowering effect of captopril (an angi-
otensin converting enzyme inhibitor) is related to a reduc-
tion in the peripheral arterial vascular resistance. The
hypotensive response to captopril is accompanied by a de-
crease in plasma aldosterone and angiotensin II levels and
an increase in plasma renin levels. In response to the de-
crease in heart rate, there is an increase in heart rate
through the baroreflex.
Insulin resistance is a common pathological finding in pa-
tients with impaired glucose tolerance as well as in sub-
jects with type II diabetes. Our results have shown that the
impaired glucose tolerance observed in dogs treated with
SNAP is due to decreased insulin binding to receptors.
This receptor defect is due to a modulation of the receptor
affinity and receptor binding sites which appears to effect
physiologic changes in insulin binding.
Analysis of the data clearly demonstrated that erythrocytes
and mononuclear leucocytes isolated from dogs acutely
treated with 20 mg/kg of SNAP have decreased ability to
bind insulin. Decreased binding was highly significant at
low unlabelled insulin concentrations, i.e. low occupancy
levels. Kinetic analysis of the data demonstrated that the
decreased binding of insulin to its receptor on erythro-
cytes and mononuclear leucocytes was attributed primari-
ly to a significant decrease in the number of insulin
receptors sites per cell, and secondarily to a reduction in
the average affinity of the receptor for insulin.
Using the Scatchard method of analysis, graphs of B/F vs
[B] for both mononuclear leucocytes and erythrocytes
[Figure 3 and Figure 4] yielded curvilinear plots with up-
ward concavity. These results suggest that the mononu-
clear leucocytes and erythrocytes from the dogs used in
this study have similar binding kinetics as those expressed
in the literature for lymphocytes, mononuclear leuco-
Figure 7
Bar graph showing the effect of 20 mg/kg of SNAP, 20 mg/kg
of captopril and 2 ml of DMSO on the number of insulin
receptor sites on the cell membranes of mononuclear leuco-
cytes. Statistical significant differences are indicated by *P <
0.05 and **P < 0.01.
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Figure 8
Bar graph showing the effect of 20 mg/kg of SNAP, 20 mg/kg
of captopril and 2 ml of DMSO on the number of insulin
receptor sites on the cell membranes of erythrocytes.
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cytes, erythrocytes and the insulin target tissues [11]. The
data in Figures 1 and 2 clearly demonstrate that insulin
binding is decreased at lower non-radioactive insulin con-
centrations, but the curves converge at the higher non-ra-
dioactive insulin levels. This pattern suggests a change in
receptor affinity. The decrease in insulin binding attribut-
ed by a decrease in receptor affinity was confirmed by the
decrease in the average affinity (K) for both mononuclear
leucocytes and erythrocytes.
To investigate whether the decrease in insulin binding was
attributed to a decrease in the number of receptor sites per
cell, the Scatchard plot for the data was analyzed. Using
this method of analysis, the x-intercept represents the
number of insulin receptor sites per cell. Calculations re-
vealed that there was a 35 % decrease in the number of re-
ceptor sites per erythrocyte in SNAP-treated dogs
compared with captopril-treated controls. There was a sig-
nificant 55 % decrease in the number of receptor sites per
mononuclear leucocyte from SNAP-treated dogs. There-
fore, the decrease in insulin binding by the acute effects of
SNAP is primarily as a result of a decrease in the number
of receptor sites per cell.
The cooperative interactions among receptor sites can be
explained in terms of the 'negative cooperativity' model.
Negative cooperativity is a frequent occurrence in hor-
mone-receptor systems in which there are site-site interac-
tions, resulting in a decrease in the apparent affinity of
receptor for insulin when fractional saturation of the re-
ceptor increases. According to this model and calculation
of the number of receptor sites using Scatchard analysis,
the decreased insulin binding observed is primarily due to
a decrease in the number of receptor sites. It can be sug-
gested that that the lower number of receptor sites per cell
in dogs treated with SNAP, could be the result of primary
alteration in the receptor or may be secondary to some
other alteration in the integrity of the membrane [12]. The
NO released from SNAP may damage mononuclear leuco-
cytes and erythrocytes in the short term with direct effects
on membrane structure, membrane fluidity, cross-linking
and function. The molecular nature and site-site interac-
tions of the receptor sites may include mechanisms such
as intra-molecular changes in tertiary or quaternary struc-
ture of the receptor, association and dissociation of the re-
ceptor molecules, clustering of receptors in the membrane
or phase transitions in the membrane itself. These changes
in membrane integrity could be responsible for the de-
creased number of receptor sites per cell. The resulting
membrane dysfunction can impair transport of glucose
across the cell membrane resulting in the observed hyper-
glycaemia.
The contributing effect of any alteration in receptor affin-
ity was evaluated by plotting the data on an average affin-
ity graph as described by De Meyts and Roth [8]. There
was a significant 22 percent decrease in the empty site af-
finity for mononuclear leucocytes, supporting the concept
that there can be alterations in both receptor affinity and
receptor sites, both contributing to the decreased insulin
binding. Some of the insulin receptor on the cell mem-
branes of erythrocytes and mononuclear leucocytes from
dogs treated with SNAP may be affected by the cytotoxic
effect of NO and may become desensitized. Desensitiza-
tion is associated with a total lack of insulin effect despite
remaining insulin receptors. Several possibilities exist to
explain the mechanism of changing receptor affinity and
desensitization. Firstly, fluidity may be an important fac-
tor in modulating insulin binding and action. Secondly,
the insulin receptor may be covalently associated with an-
other protein that modulates receptor affinity. It is there-
fore a possibility that NO released from SNAP may alter
the interaction of insulin with its receptors, thus affecting
the ability of insulin to differentially regulates its receptor
and this regulator protein [13]. Nitric oxide may also af-
fect the formation of the insulin receptor complex. A third
possibility is that the receptor undergoes some form of
post-translational modification that alters binding and
signal transmission properties [14]. The post-translational
modification could involve a change in the redox state of
the receptor. The insulin receptor is composed of major
sub-units linked by disulfide bonds to various oligomeric
forms. Reduction of the oxidized forms of the receptor
could modify the affinity of insulin [15].
Both circulating erythrocytes and mononuclear leucocytes
exhibit insulin receptors. The most remarkable difference
between these two cell types is the age dependence of the
insulin receptor on erythrocytes. Clearly major perturba-
tions in the mean cell age of an erythrocyte preparation
will have some effect on insulin binding. Therefore there
is more variability in insulin binding to erythrocytes than
mononuclear leucocytes at the limiting, low bound/free
ratios of 125-I-insulin. This variability affects the affinity
profiles derived from this data. The advantage of using
these circulating blood cells for investigating the receptor
status in human and animals is that they are more easily
accessible than cells of primary insulin target organs, such
as adipocytes and muscles. It has been found that the
characteristic of insulin binding to human adipocytes (in-
cluding affinity constants for the binding reaction) were
similar to the characteristics of insulin binding to mono-
nuclear leucocytes in obese subjects [16]. Other studies
have also confirmed that changes in insulin receptors of
mononuclear leucocytes seem to mirror the events of
more traditional insulin target tissues [17]. Therefore
mononuclear leucocytes represents a more uniform pop-
ulation of cells capable of same receptor-mediated func-
tion as adipocytes, providing a clearer reflection of the
insulin receptor status in target tissues.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/1
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The main objective of the study was to evaluate any bind-
ing abnormalities in dogs with impaired glucose tolerance
as a result of treatment with the nitric oxide donor, S-ni-
troso-N-acetylpenicillamine. This result is useful in eluci-
dating the possible diabetogenicity of nitric oxide.
Whether or not NO plays a role in the inhibition of insu-
lin action is presently under investigation in our laborato-
ry. We will examine some physiological assessment of the
cells and measurement of post-receptor signaling such as
tyrosine kinase activity, insulin receptor substrate-1 (IRS-
1) phosphorylation, and phosphotidylinositol 3-kinase
activity.
Conclusion
In summary, the present report demonstrated that im-
paired glucose tolerance observed in SNAP-treated is asso-
ciated with a decrease in insulin receptor binding. The
mechanism of decreased insulin binding was due prima-
rily to a significant reduction in the number of receptor
sites per cell and to a lesser extent, a reduction in the aver-
age receptor affinity. These findings for the first time sug-
gest a novel role of NO as a modulator of insulin binding.
Materials and Methods
Animals – Experimental design
The protocol was conducted in accordance with the guide-
lines of the University of the West Indies Animal Commit-
tee. Eighteen normal Mongrel dogs (9 males and 9
females) of 2–3 years, with average weight of 11 ± 0.4 kg
were obtained from the Pre-Clinical Animal House of the
Department of Basic Medical Sciences, University of the
West Indies. The animals were maintained in the animal
house under the supervision of attendants and a veteri-
nary consultant. Dogs were fed on a diet of Purina Labo-
ratory Chow (Purina, St. Louis MO. U.S.A.) and water
administered ad libitum.
The dogs were divided into three groups, test and controls.
An oral glucose tolerance test was performed on each dog.
Briefly, after an 18-h fast, dogs were anaesthetized with so-
dium pentabarbital (30 mg/kg i.v.). Subsequently, the
fasting blood sample was taken and in control experi-
ments 20 mg/kg body weight of captopril (Sigma Chemi-
cals Co. Ltd. St. Louis MO. USA) dissolved in water was
administered intravenously. In test experiments, S-ni-
troso-N-Acetylpenicillamine (SNAP; Sigma Chemicals
Co. Ltd. St. Louis MO. USA) was dissolved in 2 ml of
dimethyl sulphoxide (DMSO at a concentration of 0.0014
mol/L) and administered at 20 mg/kg body weight to the
dogs. Additional blood samples were collected 1.5-h after
administration of a glucose load of 1.75 g/kg body weight.
In a previous study by McGrowder et al. [9] pilot experi-
ments were carried out where a low dose of 5 mg/kg body
weight of SNAP or captopril was first administered and its
effect on the blood glucose observed during oral glucose
tolerance test. Subsequent experiments involved increas-
ing the doses of SNAP and captopril, based on the effect
of the previous dose on the blood glucose levels. The re-
sult showed that SNAP at 20 mg/kg had a significant effect
on blood glucose levels especially at the 1.5-h time point,
while a similar dose of captopril had little or no effect. In
this study blood samples were taken at the 1.5-h time
point. Each sample was collected in an EDTA tube and im-
mediately placed on ice for subsequent biochemical anal-
ysis.
Preparation of purified erythrocytes
The mononuclear leucocytes and erythrocytes were sepa-
rated using a Percoll density gradient. Mononuclear leuco-
cytes were separated from the erythrocytes by the use of
pasteur pipettes. The erythrocytes receptor assay was per-
formed according to a modification of the method by
Ghambir et al [18]. The erythrocytes were washed three
times by centrifugation (4°C, 4500 rpm) in 10 ml of buff-
er G containing 1% human serum albumin, (pH 7.8) for
10 minutes. On each occasion, the supernatant was re-
moved and the cells re-suspended in buffer G, and re-
spun. After the final wash of the cells, the supernatant was
removed and the cells were left in 4 ml of buffer G con-
taining 1 % human serum albumin. This suspension con-
tained 4–6 ×  109 cells/ml.
Preparation of purified mononuclear leucocytes
Mononuclear leucocytes were re-suspended in 4 ml of
cold Buffer M and centrifuged at 1100 rpm for 10 minutes
at 4°C. This was repeated three times, and on each occa-
sion the supernatant was removed and the cells re-sus-
pended in buffer M. After the final washing, the cells were
left in 1 % human serum albumin (approximately 2 ml)
in buffer M. The mononuclear leucocytes had a concentra-
tion of 1.70 – 2.00 ×  107 cells/ml.
Binding of 125-I to mononuclear cells and erythrocyte cells
Receptor binding were evaluated by the use of the Scatch-
ard analysis of competitive-inhibition curves, which is a
modification of the original technique described by Gam-
bir et al [18]. Lyophilized unlabelled non-radioactive in-
sulin (10 mg; Sigma porcine, 23.5 U/mg, Sigma Chemical
Co., St. Louis, MO USA) was reconstituted in 0.1 M HCl
(10 ml) and 100 µl quantities were dispensed and stored
at -70°C until required. Monoiodinated A14 [125-I] insulin
(Amershan, Arlington Heights, IL USA; specific radioactiv-
ity 50 µCi) was dissolved in deionised water (500 µl) and
aliquots of 5 µl stored at -70°C until needed.
One hundred and fifty (150) µl aliquots of the washed
erythrocyte suspension were added to a series of Eppen-
dorf tubes in triplicate. To each sample tube was added,
standard (50 µl) and 125-I-insulin (50 µl) and the incubat-
ed for 3 hours. Similar experiments were carried out usingBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/1
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mononuclear leucocytes. The mononuclear leucocyte re-
action was stopped with cold buffer M and the tubes were
centrifuged at 1100 rpm for 2 minutes. The cells were
washed twice, and the radioactivity of the pellet was deter-
mined using a Gamma Counter (Abbott Auto Logic Gam-
ma Counter). The erythrocyte reaction was stopped by
adding 1 ml of cold saline and centrifuged at 1100 rpm for
1 minute. The supernatant was discarded and 100 µl of 40
% formalin was added to harden the red cell pellet. The ra-
dioactivity of the pellet was also determined using a Gam-
ma Counter.
The data was analyzed by Scatchard analysis [19]. The re-
ceptor affinity and receptor numbers were derived for the
physiological range of insulin i.e. between 0.1 and 100
ng/ml. Specific insulin binding (SB) was calculated as the
percentage of radioactive insulin bound by 4 ×  109 and 2
×  106 cells/ml for erythrocytes and mononuclear leuco-
cytes, respectively. Non-specific binding was assessed by
the amount of radioactive insulin bind in the presence of
100 ng/ml unlabelled insulin.
Competitive binding curves were obtained for each eryth-
rocyte and mononuclear leucocyte suspension. From
these curves, the insulin receptor affinity and number of
the receptor sites were determined by the Scatchard anal-
ysis [19].
Cell binding analysis
The results of the binding studies are presented in three
ways: (1) the percentage binding of 125-I-insulin as a func-
tion of the total insulin concentration (competitive
curve), (2) the bound-free insulin ratio plotted as a func-
tion of the bound insulin (Scatchard plot) and, (3) the av-
erage affinity profile calculated according to the method
of De Meyts and Roth [8]. The total binding capacity or
concentration of the binding sites was derived from the
point where the linear extrapolation of the curve inter-
cepts the horizontal axis and this was used to calculate the
number of receptor sites per cell [19].
Experimental data suggest that the insulin receptor consist
of homologous binding sites that undergo negatively co-
operative site-site interactions such that the affinity of the
receptors for insulin is inversely related to the receptor oc-
cupancy. The average affinity profile expresses the rela-
tionship between the average affinity for insulin (K) and
the receptor occupancy (Y). The average affinity falls as a
function of receptor occupancy (negative co-operativity)
until the lowest observable affinity (Kf) is reached. The
fractional occupancy necessary to produce Kf is designated
yf, and Ke represents the highest observable affinity of the
receptors and is exhibited in the native or 'empty site'
state.
Calculations and statistical analysis
All results shown in the figures are expressed as means ±
S.E.M. Integrated area under the curve (iUAC) was calcu-
lated by subtracting the rectangle corresponding to the ba-
sal value from the total area under the curve [20]. Analysis
of the data was done using the Sigma Plot and Sigma Sta-
tistics software packages (Jandel Scientific). To evaluate
the effects of SNAP and captopril the biochemical param-
eters, values for each group were compared by either a
paired student's test or two-way analysis of variance
(ANOVA) followed by the Bonferroni multiple compari-
son test [21]. P values less than 0.05 was considered to in-
dicate significance in all cases.
Abbreviations
SNAP, S-nitroso-N-acetylpenicillamine; DMSO; dimethyl
sulfoxide; NO, nitric oxide, DNA, deoxyribonucleic acid;
cGMP, cyclic guanosine monophosphate; SB, specific in-
sulin binding.
Acknowledgements
This work was supported by a grant from the Mona Campus Committee 
for Graduate Studies, University of the West Indies.
References
1. Wink DA, Mitchell JB: Chemical biology of nitric oxide: insights
into regulatory, cytotoxic, and cytoprotective mechanisms
of nitric oxide. Free Radicals Biol. Med 1988, 25:434-456
2. Cooke JP, Andon N, Loscalzo J: S-nitrosocaptopril. II – Effect
vascular reactivity. J. Pharmacol. Exper. Ther 1989, 249:730-734
3. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA: Nitric oxide
directly activates calcium dependent potassium channels in
vascular smooth muscle. Nature 1994, 368:850-853
4. Kaneto H, Fujii J, Han GS, Suzuki K: Apoptotic cell death trig-
gered by nitric oxide in pancreatic beta-cells. Diabetes 1995,
44:733-738
5. Zhang J, Dawson VL, Dawson TM, Snyder SH: Nitric oxide activa-
tion of poly (ADP-ribose) synthetase in neurotoxicity. Science
1994, 263:687-689
6. Radons J, Heller B, Burke A, Hartmann B, Rodriquez ML, Kroncke
KD, Burkart V, Kolb H: Nitric oxide toxicity in islet cells in-
volves poly (ADP-ribose) polymerase activation and con-
comitant NAB+ depletion.  Biochemistry Biophysics Res.
Communication 1994, 199:1270-1277
7. Roth J: Peptide hormone binding to receptors: a review of di-
rect studies in vitro. Metabolism (Clin. Exp.) 1973, 22:1059-1073
8. DeMeyts P, Roth J, Neville DM, Gavin JR, Lesniak MA: Insulin's in-
teractions with its receptors – experimental evidence for
negative co-operativity.  Biochem. Biophys. Res. Commun 1973,
55:154-165
9. McGrowder D, Ragoobirsingh D, Dasgupta T: Effect of s-nitroso-
N-acetyl-penicillamine administration on glucose tolerance
and plasma levels of insulin and glucagon in the dog. Nitric Ox-
ide: Biology and Chemistry 2001, Vol. 5. No. 4,:402-412
10. Winocur P, Waldek S, Anderson DC: Captopril and blood glu-
cose. Lancet 2:461
11. Khan CR, Freychet P, Roth J: Quantitative aspects of the insulin-
receptor interaction in liver plasma membranes. J. Biol. Chem
1974, 249:2249-2257
12. Slater TF: Free radical mechanisms in tissue injury. Biochem. J
1984, 22:1-15
13. Harmon JT, Khan CR, Kempner ES, Schlegel W: Characterization
of the insulin receptor in its membrane environment by ra-
diation inactivation. J. Biol. Chem 1980, 255:3412-3419
14. Kasuga M, Zick Y, Blithe DL, Crettaz M, Khan CR: Insulin stimu-
lates tyrosine phosphorylation of the insulin receptor in a
"cell – free" system. Nature 1982, 298:667-669BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/1
Page 10 of 10
(page number not for citation purposes)
15. Massague J, Czech MP: Role of disulphides in the subunit struc-
ture of the insulin receptor. J. Biol. Chem 1982, 257:6729-6738
16. Soll AH, Golfine J, Roth CR, Khan CR, Neville DM: Thymic lym-
phocytes in obese (ob/ob) mice. A mirror of the insulin re-
ceptor defect in liver and fat. J Biol. Chem 1974, 249:4127-4131
17. Olefsky JM, Jen P, Reaven GM: Insulin binding to isolated human
adipocytes. Diabetes 1974, 23:565-571
18. Ghambir KK, Archer JA, Bradley CJ: Characteristics of human
erythrocyte insulin receptors. Diabetes 1977, 27:701-708
19. Scatchard G: The attraction of proteins for small molecules
and ions. Ann N.Y. Acad. Sci 1949, 51:660-672
20. LeFloch JP, Escuyer P, Baudin E, Baudon D, Perlemuter L: Blood glu-
cose area under the curve: Methodological aspects. Diabetes
Care: 1990, 13:172-175
21. Godfrey K: Statistics in practice: comparing the means of sev-
eral groups. N Engl J. Med 1985, 313:1450-1456
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com